nodes	percent_of_prediction	percent_of_DWPC	metapath
Droxidopa—Hyperpyrexia—Medroxyprogesterone Acetate—uterine cancer	0.0683	0.157	CcSEcCtD
Droxidopa—PAH—renal system—uterine cancer	0.0483	0.0857	CbGeAlD
Droxidopa—ADRB3—female reproductive system—uterine cancer	0.0302	0.0536	CbGeAlD
Droxidopa—Blood pressure increased—Progesterone—uterine cancer	0.0281	0.0644	CcSEcCtD
Droxidopa—DDC—renal system—uterine cancer	0.0276	0.0489	CbGeAlD
Droxidopa—ADRB3—female gonad—uterine cancer	0.0275	0.0488	CbGeAlD
Droxidopa—Blood pressure increased—Medroxyprogesterone Acetate—uterine cancer	0.0254	0.0583	CcSEcCtD
Droxidopa—ADRA1D—epithelium—uterine cancer	0.0229	0.0406	CbGeAlD
Droxidopa—DDC—female reproductive system—uterine cancer	0.0221	0.0392	CbGeAlD
Droxidopa—ADRA1B—renal system—uterine cancer	0.0217	0.0385	CbGeAlD
Droxidopa—SLC16A10—epithelium—uterine cancer	0.0204	0.0361	CbGeAlD
Droxidopa—Cardiac failure congestive—Medroxyprogesterone Acetate—uterine cancer	0.0204	0.0467	CcSEcCtD
Droxidopa—SLC16A10—mammalian vulva—uterine cancer	0.0177	0.0314	CbGeAlD
Droxidopa—ADRA1D—female reproductive system—uterine cancer	0.017	0.0302	CbGeAlD
Droxidopa—ADRA2C—myometrium—uterine cancer	0.016	0.0283	CbGeAlD
Droxidopa—Urinary tract infection—Progesterone—uterine cancer	0.0153	0.035	CcSEcCtD
Droxidopa—SLC16A10—female reproductive system—uterine cancer	0.0151	0.0269	CbGeAlD
Droxidopa—Urinary tract infection—Medroxyprogesterone Acetate—uterine cancer	0.0138	0.0317	CcSEcCtD
Droxidopa—SLC16A10—vagina—uterine cancer	0.0137	0.0243	CbGeAlD
Droxidopa—SLC6A2—decidua—uterine cancer	0.0134	0.0237	CbGeAlD
Droxidopa—ADRA1A—epithelium—uterine cancer	0.0132	0.0233	CbGeAlD
Droxidopa—DDC—lymph node—uterine cancer	0.0129	0.0229	CbGeAlD
Droxidopa—ADRA2A—myometrium—uterine cancer	0.0127	0.0226	CbGeAlD
Droxidopa—ADRA2C—uterine cervix—uterine cancer	0.0124	0.0221	CbGeAlD
Droxidopa—ADRB1—female reproductive system—uterine cancer	0.0124	0.0219	CbGeAlD
Droxidopa—ADRA1A—renal system—uterine cancer	0.0122	0.0217	CbGeAlD
Droxidopa—ADRA2C—decidua—uterine cancer	0.0118	0.021	CbGeAlD
Droxidopa—ADRA2C—renal system—uterine cancer	0.0116	0.0206	CbGeAlD
Droxidopa—Cardiac failure congestive—Etoposide—uterine cancer	0.0115	0.0263	CcSEcCtD
Droxidopa—ADRA2C—endometrium—uterine cancer	0.0112	0.0199	CbGeAlD
Droxidopa—Syncope—Progesterone—uterine cancer	0.011	0.0252	CcSEcCtD
Droxidopa—ADRA2C—mammalian vulva—uterine cancer	0.0109	0.0193	CbGeAlD
Droxidopa—Loss of consciousness—Progesterone—uterine cancer	0.0108	0.0247	CcSEcCtD
Droxidopa—Hypertension—Progesterone—uterine cancer	0.0106	0.0243	CcSEcCtD
Droxidopa—SLC6A2—female reproductive system—uterine cancer	0.0105	0.0187	CbGeAlD
Droxidopa—ADRA2C—uterus—uterine cancer	0.0104	0.0184	CbGeAlD
Droxidopa—Confusional state—Progesterone—uterine cancer	0.0101	0.0231	CcSEcCtD
Droxidopa—Syncope—Medroxyprogesterone Acetate—uterine cancer	0.00998	0.0229	CcSEcCtD
Droxidopa—ADRA2A—uterine cervix—uterine cancer	0.00992	0.0176	CbGeAlD
Droxidopa—Shock—Progesterone—uterine cancer	0.00986	0.0226	CcSEcCtD
Droxidopa—Loss of consciousness—Medroxyprogesterone Acetate—uterine cancer	0.00978	0.0224	CcSEcCtD
Droxidopa—ADRA2A—decidua—uterine cancer	0.00945	0.0168	CbGeAlD
Droxidopa—Confusional state—Medroxyprogesterone Acetate—uterine cancer	0.00915	0.021	CcSEcCtD
Droxidopa—ADRA2A—endometrium—uterine cancer	0.00897	0.0159	CbGeAlD
Droxidopa—Shock—Medroxyprogesterone Acetate—uterine cancer	0.00893	0.0205	CcSEcCtD
Droxidopa—SLC16A10—lymph node—uterine cancer	0.00885	0.0157	CbGeAlD
Droxidopa—ADRA2A—mammalian vulva—uterine cancer	0.00868	0.0154	CbGeAlD
Droxidopa—ADRA2C—female gonad—uterine cancer	0.00847	0.015	CbGeAlD
Droxidopa—ADRA2C—vagina—uterine cancer	0.00842	0.0149	CbGeAlD
Droxidopa—ADRA2A—uterus—uterine cancer	0.00827	0.0147	CbGeAlD
Droxidopa—Feeling abnormal—Progesterone—uterine cancer	0.00826	0.0189	CcSEcCtD
Droxidopa—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	0.00748	0.0171	CcSEcCtD
Droxidopa—ADRA2A—female reproductive system—uterine cancer	0.00743	0.0132	CbGeAlD
Droxidopa—ADRA2A—female gonad—uterine cancer	0.00676	0.012	CbGeAlD
Droxidopa—ADRA2A—vagina—uterine cancer	0.00672	0.0119	CbGeAlD
Droxidopa—Dizziness—Progesterone—uterine cancer	0.00663	0.0152	CcSEcCtD
Droxidopa—Cardiac failure congestive—Epirubicin—uterine cancer	0.00645	0.0148	CcSEcCtD
Droxidopa—Headache—Progesterone—uterine cancer	0.00628	0.0144	CcSEcCtD
Droxidopa—SLC6A2—lymph node—uterine cancer	0.00615	0.0109	CbGeAlD
Droxidopa—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.006	0.0138	CcSEcCtD
Droxidopa—Cardiac failure congestive—Doxorubicin—uterine cancer	0.00596	0.0137	CcSEcCtD
Droxidopa—Nausea—Progesterone—uterine cancer	0.00595	0.0136	CcSEcCtD
Droxidopa—Feeling abnormal—Dactinomycin—uterine cancer	0.00584	0.0134	CcSEcCtD
Droxidopa—Headache—Medroxyprogesterone Acetate—uterine cancer	0.00569	0.013	CcSEcCtD
Droxidopa—Loss of consciousness—Etoposide—uterine cancer	0.00552	0.0126	CcSEcCtD
Droxidopa—ADRA2C—lymph node—uterine cancer	0.00545	0.00967	CbGeAlD
Droxidopa—Hypertension—Etoposide—uterine cancer	0.00542	0.0124	CcSEcCtD
Droxidopa—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.00539	0.0124	CcSEcCtD
Droxidopa—Confusional state—Etoposide—uterine cancer	0.00517	0.0118	CcSEcCtD
Droxidopa—Urinary tract infection—Epirubicin—uterine cancer	0.00438	0.01	CcSEcCtD
Droxidopa—ADRA2A—lymph node—uterine cancer	0.00435	0.00771	CbGeAlD
Droxidopa—Feeling abnormal—Etoposide—uterine cancer	0.00422	0.00968	CcSEcCtD
Droxidopa—Nausea—Dactinomycin—uterine cancer	0.00421	0.00964	CcSEcCtD
Droxidopa—Urinary tract infection—Doxorubicin—uterine cancer	0.00405	0.00928	CcSEcCtD
Droxidopa—Arrhythmia—Epirubicin—uterine cancer	0.00361	0.00828	CcSEcCtD
Droxidopa—Dizziness—Etoposide—uterine cancer	0.00339	0.00777	CcSEcCtD
Droxidopa—Arrhythmia—Doxorubicin—uterine cancer	0.00334	0.00766	CcSEcCtD
Droxidopa—Headache—Etoposide—uterine cancer	0.00321	0.00736	CcSEcCtD
Droxidopa—Syncope—Epirubicin—uterine cancer	0.00316	0.00723	CcSEcCtD
Droxidopa—Loss of consciousness—Epirubicin—uterine cancer	0.00309	0.00709	CcSEcCtD
Droxidopa—Nausea—Etoposide—uterine cancer	0.00304	0.00698	CcSEcCtD
Droxidopa—Hypertension—Epirubicin—uterine cancer	0.00304	0.00696	CcSEcCtD
Droxidopa—Syncope—Doxorubicin—uterine cancer	0.00292	0.00669	CcSEcCtD
Droxidopa—Confusional state—Epirubicin—uterine cancer	0.0029	0.00664	CcSEcCtD
Droxidopa—Loss of consciousness—Doxorubicin—uterine cancer	0.00286	0.00656	CcSEcCtD
Droxidopa—Shock—Epirubicin—uterine cancer	0.00283	0.00648	CcSEcCtD
Droxidopa—Hypertension—Doxorubicin—uterine cancer	0.00281	0.00644	CcSEcCtD
Droxidopa—Confusional state—Doxorubicin—uterine cancer	0.00268	0.00614	CcSEcCtD
Droxidopa—Shock—Doxorubicin—uterine cancer	0.00262	0.00599	CcSEcCtD
Droxidopa—Feeling abnormal—Epirubicin—uterine cancer	0.00237	0.00542	CcSEcCtD
Droxidopa—Feeling abnormal—Doxorubicin—uterine cancer	0.00219	0.00502	CcSEcCtD
Droxidopa—Dizziness—Epirubicin—uterine cancer	0.0019	0.00435	CcSEcCtD
Droxidopa—Headache—Epirubicin—uterine cancer	0.0018	0.00412	CcSEcCtD
Droxidopa—Dizziness—Doxorubicin—uterine cancer	0.00176	0.00403	CcSEcCtD
Droxidopa—Nausea—Epirubicin—uterine cancer	0.00171	0.00391	CcSEcCtD
Droxidopa—Headache—Doxorubicin—uterine cancer	0.00167	0.00382	CcSEcCtD
Droxidopa—Nausea—Doxorubicin—uterine cancer	0.00158	0.00362	CcSEcCtD
